MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (February 2018)

24 slides from MabVax Therapeutics's investor presentation, Feb 12, 2018

  1. Slide 1: Corporate Overview February 2018

    M a b Developing Unique Human Monoclonal Antibody- therapeutics Based Products for Difficult to Treat Cancers Corporate Overview February 2018 NASDAQ: MBVX www mabvax.com

  2. Slide 2: Forward Looking Statements

    ! Forward Looking Statements This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and complete

  3. Slide 3: Value Proposition: Fully human antibody discovery and development platform

    Value Proposition: Fully human antibody discovery and development platform validated across multiple antigen targets Corporate Focused on discovery and early development of therapeutic and diagnostic antibody based products Proprietary antibodies subject of potential partnering discussions CAR-T res

  4. Slide 4: Discovery Platform

    DISCOVERY PLATFORM

  5. Slide 5: Human Antibody (HuMab) Discovery Platform

    { Human Antibody (HuMab) Discovery Platform Proprietary Approach to the Discovery and Development of Novel Fully Human Antibodies for Therapeutic and Diagnostic Agents Screening Optimized Therapy Fully human antibody ‘minimizes immunogenicity. Binding sequence reflects the patient’ immune system res

  6. Slide 6: Vaccine Programs and Associated Vaccine Antigen Targets for HuMab Programs

    } Vaccine Programs and Associated Vaccine Antigen Targets Utilized for HuMab Fully Human Antibody Programs MBVX Study Name 1 Sarcoma Mv-01080P001 2 Breast 06-156 3 Melanoma 06.086 4 Ovatian-tev 10-099 ssc 08.095 6 Ovarian-Uni oss tin i 10 Neroi41491 NcTo0470574 ‘neT00597272 NcT01223235 ‘nero1349647

  7. Slide 7: Lead and preclinical programs

    Lead Op Pre Therapeutic (MVT-5873): + Chemo ‘Therapeutic (MVT-5873): Monotherapy SS Radicimmunotherapy (MVT-1075) SS ImmmunoPET imaging (MVT-2163) HuMab-Ta Deen 9 CART Sialy Lewis? =r cART-602

  8. Slide 8: Sialyl Lewis A Target: Phase and Preclinical Program

    SIALYL LEWIS? TARGET PHASE 1 AND PRECLINICAL PROGRAM Scientific Rationale and Development Strategy

  9. Slide 9: Sialyl Lewis A target rationale

    + Say Lewis (ser the HuMabSB1 target, | * sles densely expressed in milions of copy + HuMab $81 is internalized and isexprestedin over 90% of pancreatic and ‘numbers on target tumors accumulates into target cance eels 2 large percentage of Gland lung cancers ‘+ HuMaba1 especie only tothe stet target

  10. Slide 10: Integrated & Efficient Development Strategy

    Integrated & Effi (| nt Development Strategy Antibody-Based Therapeutic Agent to Treat Very Difficult Cancers Such as Pancreatic, Small Cell Lung, Gastric and Colon ‘Completed Phase 19 Established safety spectcy, ‘seeumulation on tumor, and ose strategy for RTT Completed Phase 13 Established Safety,

  11. Slide 11: Sialyl Lewis A Target: Phase Programs, MVT-5873 Therapeutic Antibody

    SIALYL LEWIS? TARGET PHASE 1 PROGRAMS MVT-5873 Therapeutic Antibody Establishes Safety and MTD

  12. Slide 12: MVT-5873 Phase 1 results in PDAC patients

    Study conducted in stage 3 and 4 PDAC patients who have failed all other therapies and have progressive disease MTD established at 1mg/kg dosed QW and Q2W Identified subset (n=13) with 250% reduction in CA19-9 levels after treatment for one cycle that remained on treatment 5.9 mo on average (vs 1.6

  13. Slide 13: MVT-5873 In Combination With First Line Chemotherapy in PDAC

    MVT-5873 In Combination With First Line Chemotherapy in PDAC All Patients in Cohort Experience Measurable + Combination with Gem/nab in first line Meaningful Reduction in Tumor by RECIST treatment of naive PDAC patients my + Cohort 2 at 0.125 mg/kg QW is generally well tolerated (one DLT) + Promisin

  14. Slide 14: MVT-2163 PET Imaging Agent

    SIALYL LEWIS? TARGET PHASE 1 PROGRAMS MVT-2163 PET Imaging Agent Establishes Safety and Targeting Mechanism

  15. Slide 15: Data Support Using the Cold-Hot Dosing Strategy for RIT Program

    Data Support Using the Cold-Hot Dosing Strategy for RIT Program MIP images of two patients illustrating decreased liver SUV after cold pre-dose at day 7 tania ae ° ? 0.17 «47 | : | (old pre-dose (me) Hot ma) old (47m + Hot (ma) SUV of normal ver decreased with __Toxicties were limited to infusion re

  16. Slide 16: HuMab-SB1 Specifically Targets CA19-9 Positive Tumor Lesions

    HuMab-SB1 Specifically Targets CA19-9 Positive Tumor Lesions Focal radiotracer uptake above background was observed in primary tumors and metastases from day 2 and continuously increased through day 7 “ + Day 7 tumor SUV,,., were as high as 101 g/ml T FOG PET SUV, values ~10 g/mL. a + High focal upt

  17. Slide 17: MVT-1075 Radioimmunotherapy (RIT)

    SIALYL LEWIS? TARGET PHASE 1 PROGRAMS MVT-1075 Radioimmunotherapy (RIT)

  18. Slide 18: RIT (MVT-1075) Phase 1a Clinical Trial

    RIT (MVT-1075) Phase 1a Clinical Trial One Cycle of Treatment + MVT-5873 Cold Dose 4 hours wai + MVT-1075 Hot Dose = MVT-5873 Cold Dose + hours ws * MVT-1075 Hot Dose Tumor Imaging and RECIST 4,1 Assessment Safety monitoring visits throughout and dosimetry completed day 8 Firstn-Human Phase 1 + Nona

  19. Slide 19: First cohort demonstrated dosimetry and organ exposure

    * First cohort demonstrated dosimetry and organ exposure as expected * Accumulation of radiolabeled antibody seen on tumor * Good correlation with diagnostic CT - + Manageable hematologic toxicities aN * Accrual is ongoing and dose escalation planned * Announcement of cohort results in first ar quar

  20. Slide 20: » \ Vi

    CORPORATE UPDATE » \ Vi

  21. Slide 21: Financial Snapshot

    M Financial Snapshot NASDAQ MBVX Share Price* $0.90 Market Cap* $23.9M 50-Day Average Volume* 348K Common Stock Outstanding/Public Float* 26.6M/24.9M Preferred Stock (Common Equivalents) 16.0M Cash and cash equivalents as of February 9,2018 $2.5M + Shae pce ylume, met cap and shares oustanding a as

  22. Slide 22: Management and Board of Directors

    } Management Management and Board of Directors Board of Directors J. David Hansen President, CEO and Charman, 4. David Hansen President, CEO and Chairman Gregory P, Hanson, CMA, MBA Chief Financial Officer Jeffrey F. Eisenberg, CEO Xenetic Biociences; Former CEO Noven Pharmaceuticals Philip O. Livin

  23. Slide 23: Successfully completed Phase 1a programs for MVT-5873 and MVT-2163

    \ Ss Successfully completed Phase 1a programs for MVT-5873 (antibody) and MVT-2163 (PET) Over 50 patients in three active clinical investigations with the HuMab-5B1 Antibody Highly encouraging early results from MVT-5873 in combination with first line chemotherapy Cohort expansion underway to confir

  24. Slide 24: MabVax Therapeutics

    M a b Developing Unique Human Monoclonal Antibody- therapeutics Based Products for Difficult to Treat Cancers NASDAQ: MBVX Vie www mabvax.com

MabVax Therapeutics Holdings — Investor Presentation (February 2018) on 6ix